Literature DB >> 15887329

Candida, still number one--what do we know and where are we going from there?

Esther Segal1.   

Abstract

Candida species are considered as the most important fungal human pathogens, causing a variety of clinical entities, ranging from superficial, cutaneous-mucosal to deep-seated and disseminated infections. A vast body of scientific literature, has been accumulated on these pathogens. A review of the literature and topics for further research are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15887329     DOI: 10.1111/j.1439-0507.2005.01103.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  13 in total

1.  Blue dye and red light, a dynamic combination for prophylaxis and treatment of cutaneous Candida albicans infections in mice.

Authors:  Tianhong Dai; Vida J Bil de Arce; George P Tegos; Michael R Hamblin
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Antimicrobial blue light inactivation of Candida albicans: In vitro and in vivo studies.

Authors:  Yunsong Zhang; Yingbo Zhu; Jia Chen; Yucheng Wang; Margaret E Sherwood; Clinton K Murray; Mark S Vrahas; David C Hooper; Michael R Hamblin; Tianhong Dai
Journal:  Virulence       Date:  2016-02-24       Impact factor: 5.882

3.  Inhibition of specific electron transport pathways leads to oxidative stress and decreased Candida albicans proliferation.

Authors:  Fernando Ruy; Anibal E Vercesi; Alicia J Kowaltowski
Journal:  J Bioenerg Biomembr       Date:  2006-10-12       Impact factor: 2.945

4.  Candida albicans and Candida tropicalis in oral candidosis: quantitative analysis, exoenzyme activity, and antifungal drug sensitivity.

Authors:  Karen Regina Carim da Costa; Joseane Cristina Ferreira; Marilena Chinali Komesu; Regina Celia Candido
Journal:  Mycopathologia       Date:  2008-09-12       Impact factor: 2.574

Review 5.  Yeasts in the gut: from commensals to infectious agents.

Authors:  Jürgen Schulze; Ulrich Sonnenborn
Journal:  Dtsch Arztebl Int       Date:  2009-12-18       Impact factor: 5.594

6.  NB-002, a novel nanoemulsion with broad antifungal activity against dermatophytes, other filamentous fungi, and Candida albicans.

Authors:  J Pannu; A McCarthy; A Martin; T Hamouda; S Ciotti; A Fothergill; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

Review 7.  Arachidonic acid metabolites in pathogenic yeasts.

Authors:  Ruan Ells; Johan Lf Kock; Jacobus Albertyn; Carolina H Pohl
Journal:  Lipids Health Dis       Date:  2012-08-08       Impact factor: 3.876

8.  Characterising atypical Candida albicans clinical isolates from six third-level hospitals in Bogotá, Colombia.

Authors:  Giovanni Rodríguez-Leguizamón; Alessandro Fiori; Luisa F López; Beatriz L Gómez; Claudia M Parra-Giraldo; Arley Gómez-López; Carlos F Suárez; Andrés Ceballos; Patrick Van Dijck; Manuel A Patarroyo
Journal:  BMC Microbiol       Date:  2015-10-05       Impact factor: 3.605

Review 9.  Candidiasis--do we need to fight or to tolerate the Candida fungus?

Authors:  M Raska; J Bĕláková; M Krupka; E Weigl
Journal:  Folia Microbiol (Praha)       Date:  2007       Impact factor: 2.629

10.  Impact of glucose levels on expression of hypha-associated secreted aspartyl proteinases in Candida albicans.

Authors:  Leh-Miauh Buu; Yee-Chun Chen
Journal:  J Biomed Sci       Date:  2014-03-15       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.